For US residents only.

New Data Available Within Prescribing Information

TASIGNA

Want to start with the only medication FDA-approved with clinical data for treatment-free remission?

FDA updates the label of TASIGNA to reflect that certain patients with Ph+ CML in Chronic Phase may be eligible to stop treatment after sustained response

Your healthcare provider will monitor your CML during treatment with TASIGNA® (nilotinib) to see if you are in a remission. After at least 3 years of treatment with TASIGNA, your healthcare provider may do certain tests to determine if you continue to be in remission. Based on your test results, your healthcare provider may decide if you may be eligible to try stopping treatment with TASIGNA. This is called Treatment Free Remission (TFR).

  • Your healthcare provider will carefully monitor your CML during and after you stop taking TASIGNA. Based on your test results, your healthcare provider may need to re-start your TASIGNA if your CML is no longer in remission.
  • It is important that you are followed by your healthcare provider and undergo frequent monitoring to find out if you need to re-start your TASIGNA treatment because you are no longer in TFR. Follow your healthcare provider's instructions about re-starting TASIGNA if you are no longer in TFR.

If you and your healthcare provider decide that you can stop taking TASIGNA and try treatment free remission (TFR), you may have more muscle and bone (musculoskeletal) symptoms than before you stopped treatment. Symptoms may include:

  • muscle pain
  • arm and leg pain
  • joint pain
  • bone pain
  • spine pain

Click on the Medication Guide below for additional information.